- Details
- Alicia Morgans discusses key take home messages from the prostate cancer presentations from ASCO GU 2019 with Edward Schaeffer. He highlighted presentations on the diagnosis and treatment of prostate cancer across the disease continuum, developing tools for shared decision making between the physican and patient, the pros and cons of screening for prostate cancer and both the ARAMIS and the ARCHES...
|
- Details
- Alicia Morgans and Matt Cooperberg discuss the current state of contemporary active surveillance and efforts to standardize strategies nationwide. This conversation also includes discussion on informed decision making and practice patterns of active surveillance and how to tailor based on biology and genetics Biographies: Matthew Cooperberg, MD, MPH, FACS, Associate Professor, Department of Urolog...
|
- Details
- Kala Sridhar and Alicia Morgans share in a discussion on challenges and opportunities in the treatment of localized prostate cancer from the viewpoint of a medical oncologist. Conversation includes approaches for optimizing systemic therapy in localized disease and new hormonal agents, and the ICECAP initiative. Biographies: Srikala (Kala) Sridhar MD, MSc, FRCPC Medical Advisory and Research Board...
|
- Details
- Rana McKay, MD reviews the evolving landscape for the frontline treatment of metastatic RCC. Historically, patients were treated with first-line TKIs although the paradigm has been shifting over the past two years including, VEGF targeted therapy with immunotherapy and IO-IO combinations. Dr. McKay reviews the data from KEYNOTE 426 with pembrolizumab plus axitinib which demonstrated a survival ben...
|
- Details
- Sandy Srinivas, MD discusses the frontline data from the KEYNOTE 426 trial comparing pembrolizumab plus axitinib to sunitinib monotherapy in clear cell kidney cancer. 800 patients were randomized and the combination demonstrated benefit across all three outcomes measured including response rates, PFS and overall survival. Dr. Srinivas believes the tolerability for pembrolizumab plus axitinib is mo...
|
- Details
- Primo Lara and Monty Pal discuss this exciting time in the evolving paradigm for the treatment of kidney cancer. They focus their discussion on the groundbreaking data presented at ASCO GU on the KEYNOTE 426 trial which demonstrated that the combination of pembrolizumab plus axitinib was superior to the VEGF RTKI, sunitinib. Overall survival with the combination demonstrated a 46% reduction in the...
|
- Details
- Ashish Kamat, MD discusses the focus of the International Bladder Cancer Group, discussing the pathway to developing the definition of BCG-unresponsive. Today the unified definition of BCG-unresponsive disease essentially denotes those patients for whom any more BCG is futile. This has opened the door to many ongoing clinical trials. The discussion moves to review these trials, including Nadofarag...
|
- Details
- Beyond the Abstract: Effect of Puboprostatic Ligament Reconstruction on Continence Recovery after Robot-assisted Laparoscopic Prostatectomy: Our Initial Experience Abstract: Effect of puboprostatic ligament reconstruction on continence recovery after robot-assisted laparoscopic prostatectomy: our initial experience Puliatti S. et al. Effect of puboprostatic ligament reconstruction on continence re...
|
- Details
- Neal Shore discusses the current 2019 shortage of BCG with Ashish Kamat and Jonathan Rubenstein. Bacillus Calmette-Guérin (BCG) is used as first-line intravesical therapy following tumor resection of non–muscle-invasive bladder cancer. Bacille Calmette-Guérin (BCG) has been a standard of care for many patients with non-muscle invasive bladder cancer for decades.Merck & Co., Inc., has advised that...
|
- Details
- Phillip Koo hosts a lecture series which is being developed by the Prostate Cancer Outreach Working Group of the SNMMI. The Prostate Cancer Outreach Working Group focuses on increasing awareness of oncologists, urologists, and family practitioners about imaging and therapy technologies such as FACBC, bone scintigraphy, and radium-223. This lecture series will cover the complete spectrum of prostat...
|
